Researchers have developed a new way to track neuropsychiatric symptoms in lupus using magnetic resonance spectroscopy (MRS), which measures biochemical changes in the body. The study found that MRS can detect changes in metabolites, such as glutamate and glutamine, that correlate with behavioral tests.
Repeat MabThera treatment improves physical and mental aspects of quality of life measures in RA patients, with significant improvements in disease symptoms and structure. The therapy also inhibits joint structural damage, providing evidence of radiographic progression inhibition.
Researchers found that TSA and SAHA decreased cholesterol deposits and prevented macrophages from forming foam cells inside arterial walls. These findings suggest the potential for these anti-inflammatory drugs to stabilize atherosclerotic plaque and reduce acute coronary events.
A study by Mayo Clinic researchers has found that people with psoriasis are more likely to develop heart disease, including heart attacks and heart failure. The study, which followed 622 adults with psoriasis and a control group of 622 people, found significant increases in cardiovascular events among those with psoriasis.
A population-based study of 393 patients with rheumatoid arthritis found that they aged at approximately 1.25 times the rate of people in the general population. This accelerated aging was consistent with increased mortality rates among RA patients, emphasizing the need for early diagnosis and intervention to address total health.
A nationwide study of over 18 million women found that pregnant women with systemic lupus have a significantly higher risk of death or medical complications compared to those without the disease. The study suggests that these women should be closely monitored by healthcare providers and consider planning their pregnancies carefully.